Drug Approval | April 26, 2022
DCGI grants Covaxin Emergency Use Approval for children 6-12 years
Covaxin was earlier approved for children 12-18 years of age
Covaxin was earlier approved for children 12-18 years of age
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
Sputnik Light is the first component of Sputnik V
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
The vaccines are currently only authorised for emergency use in the country
However, these won’t be available at the nearest chemist store soon
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
It will be marketed under the brand name Molunamax
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
Subscribe To Our Newsletter & Stay Updated
